An update from COSCIENS Biopharma ( (TSE:CSCI) ) is now available.
COSCIENS Biopharma Inc. announced a potential delay in filing its year-end financial documents due to complexities arising from its recent merger with Ceapro Inc. The delay is attributed to the first audit of the combined entity, which revealed material weaknesses in financial controls and required additional time to address these issues. The company is working closely with auditors to complete the filings and has applied for a management cease trade order as a precaution. Despite the delay, there is no immediate impact on the company’s stock listing, and COSCIENS is not involved in any insolvency proceedings.
More about COSCIENS Biopharma
COSCIENS Biopharma Inc. is a life science company formed from the merger of Aeterna Zentaris and Ceapro Inc. It develops and commercializes a diverse range of cosmeceutical, nutraceutical, and pharmaceutical products, focusing on leveraging proprietary extraction technology to produce active ingredients from renewable plant resources.
YTD Price Performance: 21.98%
Average Trading Volume: 20,568
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $10.41M
For an in-depth examination of CSCI stock, go to TipRanks’ Stock Analysis page.